MedTrace Logo

HCV Post-Exposure Prophylaxis for Health Care Workers

NCT03313414 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-01-21

No results posted yet for this study

Summary

This is an unblinded, observational trial of sofosbuvir-velpatasvir in adult health care workers who are exposed to hepatitis C virus from needlestick injury with hollow-bore needles.

Conditions

  • Hepatitis C

Interventions

DRUG

Sofosbuvir/Velpatasvir Treatment for 14 days

14 day therapy with Sofosbuvir/Velpatasvir

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Raymond Chung, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-13
Primary Completion
2020-01-31
Completion
2020-01-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03313414 on ClinicalTrials.gov